[ad_1]
It is compact, portable and ready to use (no reconstitution required) in a single fixed dose of 3 mg.
The US Food and Drug Administration (FDA) has approved 3 mg of BAQSIMI ™ Nasal Powder (Glucagon) for the treatment of severe hypoglycemia in diabetics aged four years and older, Eli Lilly recently announced and Company. BAQSIMI is the first and only glucagon administered nasally. It has been designed for rescue in case of severe hypoglycemia. It is compact, portable and ready to use (no reconstitution required) in a single fixed dose of 3 mg.
BAQSIMI is contraindicated in patients with pheochromocytoma, insulinoma and known hypersensitivity to glucagon or to any of the excipients of BAQSIMI. Allergic reactions have been reported with glucagon and include anaphylactic shock with difficulty breathing and hypotension.
Users can sign up for direct updates on BAQSIMI's availability, patient and caregiver resources, and BAQSIMI.com's financial accessibility options. BAQSIMI should be stored in retail pharmacies a month from now.
Acquired by Lilly from Locemia Solutions in 2015, BAQSIMI is a new formulation of rescue glucagon that builds on Lilly's tradition of diabetes. Claude Piche, CEO and co-founder of Locemia Solutions, attributes to his co-founder Robert Oringeras the original inspiration of BAQSIMI.
Lilly is in talks with insurers to make BAQSIMI accessible to as many people as possible. Insured diabetics with commercial insurance can pay a minimum of $ 25 for up to two BAQSIMI devices (one pack of two or two packagings) if they use the savings card. * This ordinance is usually completed on an annual basis. Lilly may also be able to help people who do not have commercial insurance with the options offered by the Lilly Diabetes Solutions Center when BAQSIMI is available in US pharmacies. The current price in the United States for a BAQSIMI individual package is $ 280.80 and for a double package is $ 561.60.
"We understand the financial impact of diabetes management on families." Lilly is committed to making BAQSIMI affordable and accessible to as many people with diabetes as possible by ensuring access to payers. as well as our affordable offers, "said Tony Ezell, Vice President, US Connected Care and Insulins, Lilly.
[ad_2]
Source link
